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 Abstract 
Eye is delicate organ of body whose defence mechanism restricts entry of exogenous substances. Conventional 
drug delivery systems get washed off within a short period of time and results in poor ocular bioavailability. Development 
of in situ gel having protracted ocular residence time is one of the mile stone triumphs by pharmaceutical researcher for 
treatment of eye aliments. This polymeric system showed sol-to-gel phase transition by change in physiological parameters 
in pre-corneal area which includes pH, temperature or ionic interactions etc. Three types of in situ gels are well known 
based on mechanism involved in phase transition viz. temperature dependent, pH sensitive, ion activated systems. Gel 
formed after phase transitions have high viscosity along with bio-adhesive property, which increases resistance for 
instantaneous rinse off due to defence contrivance. Plus it prevents nasal-lachrymal drainage and avoids the systemic side 
effects. Recently, in situ gels have been vexed in amalgamation with another drug delivery system. It may include use of 
two or more stimuli systems together or added advantages of nano-technology. Combination of in situ gel with nano-
particles is utmost remedy for ocular treatment with water insoluble drugs.  
Keywords: In situ gel; Smart polymer; Nanotechnology; ocular bioavailability, Prolong Release. 
1. Introduction  
Eye is one of the most important sensory organ 
which converts light to an electric signals which is 
interpreted by brain [1]. It gets suffer from various diseases 
like glaucoma, dry eye syndrome, trachoma, keratitis, 
conjunctivitis etc [2]. Eye is unique organ in terms of its 
anatomical-physiological structure and defence mechanisms 
[3]. It is highly protected organ which restrict the entry of 
any exogenous substances [4]. Therefore, to target the drug 
at required ocular site in therapeutic dose is one of the most 
challenging tasks to scientist [5]. Various factors like 
nasolacrymal drainage of drug, binding of drug to 
lachrymal protein, induced lachrimation, availability of 
limited corneal area creates as barrier for absorption of drug 
through ocular route [2,6]. 
An ocular treatment mainly focuses on topical 
application than systemic administration of therapeutic 
moiety. Drug can be delivered topically by solution, 
suspension or ointment of which eye drops account for 90% 
of marketed formulations [2,7]. The reason may be 
attributed to ease of administration and patient compliance. 
Nonetheless, the ocular bioavailability is very low with 
topical drop administration [8]. 
When drug is administered topically it reaches to 
targeted site by corneal followed by the non-corneal routes. 
Corneal route is foremost important for absorption of 
ophthalmic drugs [9]. However; cornea acts as barrier for 
topical absorption of these agents [10]. Anatomical 
structure of cornea exert unique differential solubility 
requirement for drug candidate. Various factors viz. 
partition coefficient, concentration gradient, diffusivity 
plays important role in transcorneal absorption [11].   
Grass and co-workers studied the mechanism of 
corneal drug penetration from kinetic modeling point of 
view. The model was developed by relating permeability 
coefficient with partition coefficient and molecular weight. 
This model represents the cornea as a laminated membrane 
with a lipid layer (epithelium) and an aqueous layer 
(stroma). 
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The permeability coefficient of this laminated 
membrane is expressed as: 
𝐾𝑝𝑒𝑟 = 1/  
𝐿𝑠
𝐷𝑠
 + 𝐿𝑒 𝐷𝑝 + 𝑃𝐷𝑒                                     1 
Where; 
Kper = permeability coefficient,  
P = partition coefficient 
Ls and Le = thickness of stroma and epithelium  
Ds, De and Dp are apperent diffusion coefficient for 
stroma, epithelium, epithelial pores respectively 
Pores present on epithelial layer are of very small 
size and hence diffusion through pores can be neglected. 
Therefore when Dp = 0 Eq. 2 can be rearranged to give Eq. 
2 
𝐾𝑝𝑒𝑟 = 𝑃/𝑃  
𝐿𝑠
𝐷𝑠
 +
𝐿𝑒
𝐷𝑒
                                                      2 
 From Eq. 2 one can conclude that the epithelium is 
the barrier for small values of partition coefficient and the 
stroma for large values of partition coefficient [12-14]. The 
optimal log partition coefficient appears to be in the range 
of 1–3 [15].  
Additionally, normal capacity of cul-de-sac is 7-
10µl which can be extended up to 30µl without blinking 
[16]. Due to this, conventional eye drops are eliminated 
from the precorneal area immediately and only 1-10% of 
topically applied drug get absorbed [17]. Moreover, due to 
tear drainage more than 75% of the administered dose 
passes via nasolacrymal duct into the GI tract, leading to 
systemic side effects [18,19]. 
Short pre-corneal contact time combined with poor 
corneal permeability results in low ocular bioavailability 
(10% or less) and as a result, frequent instillation of 
concentrated solutions is needed in order to achieve the 
desired therapeutic effects [20,21]. A high frequency of eye 
drop instillation is associated with patient non-compliance 
[22]. It has been reported that nearly 50% of glaucoma 
patient discontinued topical ocular therapy within six month 
because of high frequency of instillation [19]. Inclusion of 
excess drug in the formulation is an attempt to surmount 
problems of bioavailability is potentially dangerous if 
drained drug solution get absorbed systemically through 
nasolacrymal duct [22,23]. 
The poor bioavailability and therapeutic response 
shown by conventional eye drops can be overcome by the 
use of novel ophthalmic drug delivery system (NODDS) 
[24]. In last two decades several NODDS have been 
developed in order to improve ocular bioavailability of 
drug. It includes aqueous gels, liposomes, nanoparticles, 
dendrimer, nanomicells, implant, contact lenses, 
nanosuspension etc [8, 20]. Additionally rapid progress in 
bioscience opens new possibilities to meet need of posterior 
treatment [25].  However these ocular drug delivery 
systems have not been used extensively because of some 
drawbacks such as blurred vision from ointment, non-
reproducibility and poor stability of liposomes, high cost of 
nano-preparation and poor patient compliance from contact 
lenses [3, 26]. 
The development of in situ gel systems has 
received significant interest of ophthalmologist over the 
past few years. In situ gel forming system has showed their 
potential in increasing the residential time because of bio-
adhesiveness of formed gel. Additionally polymers used to 
achieve in situ gelling may results in sustained release of 
drug molecules [27, 28, 29]. This system described as low 
viscosity solution that undergoes phase transition in cul-de-
sac to form viscoelastic gel. This sol-to-gel phase transition 
is due to conformational changes of polymer in response to 
physiological environment. In situ formulations are more 
acceptable for patient because they are administered as 
solution or suspension which immediately undergoes to 
gelation as come in contact with eye [30].   
Depending upon method employed to cause sol-to-
gel phase transition on ocular surface three types of in situ 
gels are widely accepted as pH triggered systems, ion-
activated systems and temperature sensitive system [5]. Use 
of in situ gel-forming polymeric formulations may increase 
patient compliance by decrease in frequency of 
administration and overall cost of treatment [31, 32]. The 
technology can be commercially acceptable, less complex 
and low manufacturing costs [3]. 
In recent years, extensive investigations have been 
dedicated to develop newer in situ gelling system which 
involved combination of one or more NODDS with in situ 
gelling systems [33]. It involved use of two different stimuli 
sensitive system together, nanoparticles loaded in situ 
systems etc. These combinations at least theoretically prove 
its benefit in modulating drug release at the ocular surface. 
Further studies are required to examine the benefits of these 
combined approaches [33, 34].    
Article will summarised concept of all approaches 
used in stimuli sensitive systems along with information of 
different polymers that can be used in respected approach, 
advance in stimuli sensitive system, FDA approved 
formulation based on concept of in situ gel and different 
evaluation parameters of in situ gel.    
1.1 Ideal properties for in situ formulations 
Physical state: Formulation should be free flowing liquid 
which allows ease of administration with reproducible dose 
delivery 
Phase transition: Upon instillation it should undergoes sol-
to-gel formation by phase transition [35]. 
Strength of gel: Formed gel should be strong enough to 
withstand the shear force in cul-de-sac which prolongs 
residence time of drug [6]. 
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1.2 Mechanism behind increase in ocular bioavailability 
Conventional ophthalmic formulations get 
eliminated within short period of time because of poor 
ocular retention. It is widely accepted that increase in 
viscosity of formulation results in more resistance to wash 
off because of which drug remain in contact at site for a 
longer period of time. Increase in contact time shows 
improved bioavailability [37].  
As in situ system undergoes phase transition in 
normal physiological condition to form viscoelastic gel, it 
can be results in increased bioavailability along with 
sustained release of drug and less or no systemic side effect 
[2]. 
 
2. Various approaches of in situ gelation 
Various approaches used for in situ gelling systems are as 
follows; 
Stimuli-responsive in situ gel system 
Temperature induced in situ gel system 
pH induced in situ gel system 
Chemically induced in situ gel system 
Ionic cross linking (Ion activated systems) 
Enzymatic cross linking 
2.1 Stimuli responsive in situ gel system 
Polymers used in stimuli responsive system are 
also known as stimuli-sensitive, intelligent, smart or 
environmentally sensitive polymer. These polymers adapt 
small external changes in environment and undergo 
relatively large and abrupt, physical or chemical changes 
[37]. These polymer systems may recognise a stimulus as a 
signal and then change their chain conformation in direct 
response [29]. 
2.1.1 Temperature induced in situ gel system 
Temperature-sensitive systems are the most 
commonly studied class of stimuli responsive polymer 
systems for ocular targeting [28]. The use of a biomaterial 
whose transitions from sol to gel is triggered by change in 
temperature is an attractive way to achieve in-situ formation 
[38]. The ideal phase transition temperature for this type of 
systems is physiologic temperature where there is no need 
of external source of heat other than that of body for 
gelation. For convenience, temperature-sensitive in situ gels 
are classified into negatively thermo-sensitive, positively 
thermo-sensitive, and thermally reversible gels [39]. 
Negative temperature-sensitive in situ gels have a lower 
critical solution temperature (LCST) and contract upon 
heating above the LCST. A positive temperature sensitive 
in situ gel has an upper critical solution temperature 
(UCST) and contracts upon cooling below the UCST 
[40,41]. 
Formulation is liquid at room temperature (20-
25°C) which undergoes gelation in contact with body fluid 
(35-37°C). Temperature increases degradation of polymer 
chains which leads to formation of hydrophobic domains 
and transition of an aqueous liquid to in situ gel [29]. 
Poloxamers, Xyloglucan, Chitosan and naturally occurring 
cellulose derivatives are most commonly used polymers in 
preparation of thermo-sensitive in situ gelling system.   
Poloxamers 
Poloxamers are a broad group of compounds that 
were introduced in the early 1950 as food additives and for 
pharmaceutical preparations. These water-soluble 
surfactants are triblock co-polymers prepared from poly 
(ethylene oxide)-b-poly (propylene oxide)-b-poly (ethylene 
oxide) i.e. PEO-PPO-PEO. They are commercially 
available as Pluronic or Poloxamers which is marketed by 
BASF Corporation. These are the most commonly used 
thermosetting polymers and could be applicable for the 
development of effective ophthalmic drug delivery [2, 40]. 
The pluronic triblock copolymers are available in 
various grades differing in molecular weights and physical 
forms. Depending upon the physical designation for the 
grades are assigned, as F for flakes, P for paste, L for liquid 
[42]. Depending upon the ratio and the distribution along 
with the chain of hydrophilic and hydrophobic subunits, 
several grads are available having different gelling 
properties. Different grades of poloxamers are shown in 
Table 1. 
Table 1: Different grade of poloxamers 
Poloxamer Pluronic ® Molecular Weight 
124 L 44 NF 2200 
188 F 68 NF 8400 
237 F 87 NF 7959 
338 F 108 NF 14600 
407 F 127 NF 12600 
Pluronics F127, which gives colourless and 
transparent gel so commonly used in the pharmaceutical 
industries. Poloxamer formulation generally increased drug 
residence time at application sites, resulting in improved 
bioavailability and efficacy. Pluronic F127 was found to gel 
at a concentration of 20 wt. % at 25 °C, which is less than 
that of the other members of the Poloxamer series [29]. 
Three principal mechanisms have been proposed 
to explain the liquid-gel phase transition after an increase in 
temperature, including; i) Gradual desolvation of the 
polymer, ii) Increased micellar aggregation, iii) The 
increased entanglement of the polymeric network. 
Xyloglucan 
Xyloglucan is a polysaccharide derived from 
tamarind seeds and is composed of a (1-4)-β-D-glucan 
backbone chain, which has (1-6)-α-D xylose branches that 
are partially substituted by (1-2)-β-D-galactoxylose. When 
xyloglucan is partially degraded by β- galactosidase, the 
U. D. Laddha and H. S. Mahajan / An insight to ocular in situ gelling systems                                                                                            34 
IJAP (2017) 06 (02)                                                                                                                                          www.ssjournals.com 
resultant product exhibits thermally reversible gelation by 
the lateral stacking of the rod like chains. The sol-gel 
transition temperature varies with the degree of galactose 
elimination. Gelation is possible only when the galactose 
removal ratio exceed to 35% [2, 43]. 
Chitosan 
Chitosan is a biodegradable, thermosensitive, 
polycationic polymer obtained by alkaline deacetylation of 
chitin [42]. Chitin is the second most abundant 
polysaccharides in nature after cellulose. The main 
commercial sources of chitin are the shell wastes of shrimp, 
crab, lobster, krill, and squid. It is a biologically safe, non-
toxic, biocompatible, and biodegradable polysaccharide. 
Being a bioadhesive polymer and having antibacterial 
activity, chitosan is a good candidate for site-specific drug 
delivery. It is linear polysaccharide consisting of (1-4)-
linked 2-amino-2-deoxy-b-D-glucopyranose which have the 
reactive amino groups and hydroxyl groups [2]. Chitosan is 
a biocompatible pH dependent cationic polymer, which 
remains dissolved in aqueous solutions up to a pH of 6.2. 
Neutralization of chitosan aqueous solution to a pH 
exceeding 6.2 leads to the formation of a hydrated gel like 
precipitate. The pH gelling cationic polysaccharides 
solution are transformed into thermally sensitive pH 
dependent gel forming aqueous solutions, without any 
chemical modification or cross linking by addition of polyol 
salts bearing a single anionic head such as glycerol, 
sorbitol, fructose or glucose phosphate salts to chitosan 
aqueous solution  [40]. 
Cellulose derivatives 
Thermo reversible gels can be prepared with 
naturally occurring polymers. Most of natural polymer 
aqueous solutions form a gel phase when their temperature 
is lowered. Some examples of natural polymers exhibiting a 
sol–gel transition include gelatin and carrageenan. At 
elevated temperatures, these polymers adopt a random coil 
conformation in solution. Upon cooling, a continuous 
network is formed by partial helix formation. Some 
cellulose derivatives are an exception to this gelation 
mechanism. At low concentrations (1–10%), their aqueous 
solutions are liquid at low temperature but get gels upon 
heating. MC and HPMC are typical examples of such 
polymers. Cellulose derivatives have high phase transition 
temperature which can be lowered by chemical or physical 
modification [2]. 
2.1.2 pH induced in situ gel system 
Sol to gel phase transition is achieved by change in 
pH. All pH-sensitive polymers contain pendant acidic or 
basic groups that either accept or release protons in 
response to changes in environmental pH. The polymers 
with a large number of ionizable groups are known as 
polyelectrolytes. Swelling of in situ gel increases as 
external pH increases in case of weakly acidic (anionic) 
groups, but decreases if polymer contains weakly basic 
(cationic) groups. Most of anionic pH-sensitive polymers 
are based on PAA (Carbopol, carbomer) or its derivatives. 
Sol to gel transition occurs when pH rises from 4.2 to 7.4. 
At higher pH polymer forms hydrogen bonds with mucin 
which leads to formation of in situ gel [2]. The formulation 
with pH‐triggered in situ gel is therapeutically efficacious, 
stable, non‐irritant and provided sustained release of the 
drug for longer period of time than conventional eye drops 
[4]. 
2.1.3 Polymer used in pH induced in situ gel system 
Carbomer 
It is cross-linked poly (acrylic acid), commercially 
available as Carbopol. It is widely used in ophthalmic 
formulation in order to enhance pre-corneal retention of 
drug [29]. Carbomer are white-coloured, „fluffy‟, acidic, 
hygroscopic powders with a characteristic slight odour. It 
has glass transition temperature in range of 100-105
o
C [44, 
45]. Carbopol offers the advantage of exhibiting excellent 
mucoadhesive properties as compared to other polymers. 
Interaction between mucin and poly (acrylic acid) occurred 
by four mechanism viz. electrostatic interaction, hydrogen 
bonding, hydrophobic interaction and inter diffusion. It is 
pH sensitive polymer which shows sol to gel transition in 
aqueous solution when pH is raised above 5.5 [2]. It 
required in high concentration to form stiff gel. At higher 
concentration it forms highly acidic solution which is not 
easily neutralized by buffer action of tear fluid and results 
in ocular irritation. Reduction in its concentration without 
affecting the gelling capacity and viscosity can be achieved 
by addition of viscosity increasing polymers such as HPMC 
[20, 22, 46]. It is included in US-FDA inactive ingredient 
guidelines and in non-parenteral medicines licensed in 
Europe. 
2.1.4 Chemically induced in situ gel system 
Ion activated systems 
Ion activated gelling system is triggered by cations 
present in eye tear fluid like Na
+
, Ca
+2
 and Mg
+2
. Generally 
anionic polymers are used in the formation of ion sensitive 
drug delivery system. Polymers like sodium alginate, 
gelrite, tamarind gum, gellen gum are used in combination 
with other polymers like MC and HPMC to increase the 
effect. They provide sustain release of drug by providing 
mucoadhesivenes. This system based on the mechanism of 
ionic interaction of ions of polymer and divalent ions of tear 
fluid. As soon as anionic polymers come in contact with 
cationic ions they convert into gel [2, 29].  The 
concentration of Na+ in human tear is 2.6 g/l is particularly 
suitable to cause gelation of material when formulation 
administered topically [47]. 
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2.1.5 Polymers used in ion activated in situ gelling system 
Gellan gum 
It is linear, anionic hetero polysaccharide secreted 
by the microbe Sphingomonaselodea (formerly known as 
Pseudomonaselodea) which is available with brand name as 
Gelrite TM, Kelcogel TM. It can be produced by aerobic 
fermentation and then isolated from the fermentation broth 
by alcohol precipitation. The polymer back bone consists of 
glucose, glucuronic acid, and rhamnose in the molar ratio 
2:1:1. It undergoes gelation by both temperature sensitive 
or cations induced mechanism. Mechanism of gelation 
involves the formation of double helical junction zones 
followed by aggregation of the double helical segments to 
form a three-dimensional network by complexation with 
cations and hydrogen bonding with water. Upon instillation 
into eye it undergoes phase transition in the presence of 
monovalent and divalent cations (Na
+
, K
+
, Ca
+2
) [42, 48]. 
Alginic acid  
Alginic acid is a linear block copolymer 
polysaccharide consisting of β-D-mannuronic acid and α-L-
glucuronic acid residues joined by 1, 4-glycosidic linkages. 
The proportion of each block and the arrangement of blocks 
along the molecule vary depending on the algal source [49]. 
Ratio of β-D-mannuronic acid and α-L-glucuronic acid 
plays important role in determination of various properties 
of polymer such as mechanical strength, porosity etc.  
Alginate with a high guluronic acid content will improve 
the gelling properties and reduces concentration of polymer 
required to form stiff gel. The alginate forms 3-dimensional 
ionotropic hydrogel matrices by interaction with calcium 
ions and results in the formation of homogeneous gel. It is 
biodegradable, non-toxic polymer approved by several 
regulatory authorities [50].   
Enzymatic cross linking 
In this approach, in situ formation is catalysed by 
natural enzymes present in tear fluid. It has not been 
investigated widely but seems to have some advantages 
over other approaches like no need of any potential and 
harmful chemicals [1]. 
Table 2 contains some examples of the use of 
stimuli responsive polymers in ophthalmic pharmaceutical 
systems.   
 
Table 2: Example of different in situ gelling systems 
Mechanism Drug Polymers Release 
extension 
Reference 
Temperature  Betoxolol pluronic F-127 and HPMC-E 50 LV upto 7 h Geethalakshmi et al., 
2013 
Temperature  Timolol Maleate Poly (N isopropylacrylamide) –chitosan 
(PNIPAAm–CS) 
Upto 12 h Cao, et al., 2007 
Temperature Ciprofloxacin Pluronic and Chitosan 
 
upto 8 h  Varshoza, et al., 
2008 
Temperature Pilocarpin 
hydrochloride  
Xyloglucan and pluronic F-127 Upto 7 h  Miyazaki, 2001 
Temperature  Ketorolac 
tromethamine (KT) 
methylcellulose (MC) and  
hydroxypropylmethyl cellulose (HPMC) 
Upto 4 h Manas BHOWMIK-
2011 
pH Sinomenine HCl (SIN) Carbopol 940 and HPMC K4M Upto 8 h Song et al., 2013 
pH Baicalin  Carbopol 974P and HPMC E4M Upto 8 h Wu et al. 2011 
pH Timolol Maleate Carbopol/Chitosan Upto 24 h Gupta et al., 2010 
pH Ciprofloxacin Carbopol 940 and Methocel E50LV Upto 8 h Srivdya etal., (2001) 
Ion activated Diclofenac Potassium sodium alginate and HPMC Upto 10 h Subimol et al., 2013 
Ion activated  Ketorolac 
tromethamine 
Gelrite Upto 6 h Sirish V, et 
al.,(2010), 
Ion activated Ofloxacin Sodium alginate and HPC Upto 7 h Sindhu A, et al., 
(2009) 
While table 3 contains FDA approved marketed in situ gel. This clearly indicates that formulation of ophthalmic in 
situ gel is feasible on lab scale as well as on large scale.  Also it has ability to sustain the release of drug. 
 
Table 3: List of FDA approved ocular in situ gel 
Sr. No. Product Name API Polymer Type of in situ gel Indication 
1 Azasite Lidocaine HCl Poloxamer 407 Temperature sensitive Bacterial conjunctivitis 
2 Pilopine HS Pilocarpine HCl Carbopol 940 pH sensetive Glaucoma 
3 Timoptic XE Timolol Maleate Gellan gum Ion activated Glaucoma 
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3. Combined approaches with in situ gel for 
enhanced ocular bioavailability 
3.1 Ophthalmic formulations with two or more stimuli 
responsive polymers 
The ophthalmic formulations containing different 
stimuli responsive polymers to obtained improved sustained 
or controlled drug release explore an excellent strategy. The 
main idea is that formulation contains combination of 
polymers which undergoes phase transition in response to 
simultaneous variations in at least two physical parameters 
such as pH, temperature and ionic strength [27]. 
 Use of two stimuli responsive polymers together 
gives excellent gelation properties.  Also, single polymer 
based systems requires high concentration of polymer to 
achieve desired viscosity of in situ gelling system. This may 
creates stability related issues of formulation e.g.  Carbopol. 
It is pH sensitive polymer which shows sol to gel transition 
in aqueous solution when pH is raised above 5.5. It is 
polyacrylic acid (PAA) which is required in high 
concentration to form stiff gel. At higher concentration it 
forms highly acidic solution which is not easily neutralized 
by buffer action of tear fluid [20, 22, 46]. 
Lin and Sung [27] developed ophthalmic in situ 
gelling system of pilocarpine hydrochloride consist of 
carbopol, pluronic and combination of carbopol / pluronic 
at different concentration level. Formulations were 
evaluated for various parameters viz.  rheological 
properties, in vitro release as well as in vivo 
pharmacological response. It was found that mixture of 
0.3% carbopol and 14% pluronic solutions showed a 
significant enhancement in gel strength at the physiological 
condition; this gel mixture was also found to be free 
flowing at pH 4.0 and 25
o
C. Both the in vitro release and in 
vivo pharmacological studies indicated that the carbopol / 
pluronic solution had the better ability to retain drug than 
the carbopol or pluronic solutions alone. The results 
demonstrated that the carbopol / pluronic mixture can be 
used as an in situ gelling vehicle to enhance the ocular 
bioavailability.  
  Basaran and Bozkir [61] developed and 
evaluate ophthalmic in situ gelling systems of ciprofloxacin 
hydrochloride with Carbopol 934 and Poloxamer 407. 
Hydroxypropyl-β-cyclodextrin was used in order to 
increase the stability of ciprofloxacin hydrochloride. The 
developed formulations were found therapeutically efficient 
and provided sustained release of the drug over an 8 h 
period. 
3.1.1 Nano in situ gel 
Now a day‟s nano-technology is the most 
emerging concept in pharmaceutical filed [62]. Several new 
preparations based on nano-technology have been 
developed to protract ocular residence time as well as 
enhanced bioavailability.  Use of nano-particles has led to 
the solution of various solubility related problems of poorly 
soluble drugs especially BCS class II & IV [63].  However, 
nanoparticles are non-muco adhesive, so are drained out of 
eyes quickly [64]. This problem can be overcome by 
suspending fabricated nano-particles in an in situ gelling 
vehicle which undergoes sol to gel phase transition upon 
exposure to physiological conditions [33,65]. This results in 
increasing the pre-corneal residence time of the nano-
particles and enhancing ocular bioavailability.   
This combined approach of in situ gel with nanoparticles is 
termed as “nanoparticle laden in situ gel” [64].  
 Nagarwal et al. [33] investigated a novel nano in 
situ gel forming system of 5-Fluorouracil (5-FU) for its 
potential use for conjunctival/corneal squamous cell 
carcinoma (CCSC). The study was conducted in two steps, 
in the first step PLA nanoparticles were prepared and 
characterized which were dispersed in sodium alginate 
solution yielding the modified nano in situ system. In vitro 
and in vivo study of prepared nano in situ gel was 
conducted in simulated tear fluid and in rabbit eye 
respectively. In vitro experiments indicated a diffusion 
controlled release of 5-FU from modified nano in situ 
system upto 8 h with high burst effect.  Modified nano in 
situ gel system (MNS) showed significant increased the 
Cmax and AUC in aqueous humor as compared to 5-FU 
solution and PLA nanoparticles.   
 Gupta et al. [65] developed sparfloxacin poly-
lactic-co-glycolic acid nanoparticle and incorporated in 
chitosan in situ gel for ophthalmic delivery. The 
formulation was tested for various physicochemical 
properties. Gamma Scintigraphy showed good retention 
over the entire pre-corneal area.  
 Sathyavathi et al. [66] prepared brimonidine 
tartrate niosomal in situ gels for glaucoma treatment.  
Niosomes formulated with span 60 showed highest 
entrapment efficiency. In situ gelling of niosomal drops was 
formulated by using Carbopol 940 and HPMC K 15 M. 
Antiglaucoma activity of the prepared gel formulations 
showed more significant and sustained effect  over period 
of 480 min  than marketed and niosomal drops. Overall in 
situ gel can be summarised by using Fig. 1. 
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Fig. 1: Overview on in situ gel 
 
4. Evaluation of in situ gel  
Ocular in situ gel can be tested for various 
parameters in order to ensure that prepared formulation 
satisfy safety guidelines for ODDS.  
4.1 Visual appearance and clarity  
Visual appearance and clarity of prepared in situ 
formulation is checked for presence of any particulate 
matter under fluorescent light against a white and black 
back ground [67]. 
pH 
pH affects both solubility as well as stability of 
drug in ophthalmic formulations. It should be such that the 
formulation will remain stable at that pH at the same time 
there would no irritation to the patient upon administration. 
It is measured by digital pH meter [68]. 
Gelling capacity 
Gelling capacity of formulation is determined by 
placing a drop of the formulation in a vial containing 2.0 ml 
of freshly prepared simulated tear fluid and time taken for 
its gelling is noted [6].  
Tonicity 
Isotonicity is important characteristics of 
ophthalmic formulation which has to be maintained to 
prevent any tissue damage or irritation to the eye. It refers 
to the osmotic pressure exerted by salts in aqueous solution. 
Ophthalmic formulation must possess osmotic pressure 
within the range of 290-310 mOsmol/kg. Tonicity is 
measured by using osmometer [7, 69]. 
4.2 In vitro drug release study  
In vitro drug release study is done by using Franz 
diffusion cell. In receptor compartment freshly prepared 
ATF is placed. Dialysis membrane is placed in between 
receptor and donor compartments. Whole assembly is kept 
on the thermostatically controlled magnetic stirrer to 
simulate in vivo conditions and temperature of medium is 
maintained at 37
o
C ± 0.5
o
C. Medium is continuously stirred 
at 20 rpm. 1ml of formulation is placed in donor 
compartment. Sample (0.5ml) is withdrawn at 
predetermined time interval and same is replaced by ATF. 
Samples are analysed either on UV spectrophotometer or 
HPLC [16, 51]. 
4.3 Rheological studies  
Viscosity determination of in situ formulation is 
carried out on Brookfield viscometer having small volume 
adapter. Viscosity is measured before and after gelation by 
increasing angular velocity gradually from 0.5 to 100 rpm 
[61].  
4.4 Texture analysis 
The consistency, firmness, and cohesiveness of in 
situ gel are assessed by using texture profile analyzer. This 
mainly indicates gel strength and easiness in administration. 
Texture analysis provides information on hardness, 
compressibility and adhesiveness which can be correlated 
with various parameters like ease of removal from 
container, good spreadability on corneal surface and 
adherence to mucous layer in order to prolong residence 
time [5]. 
4.5 Transcorneal permeability study 
Transcorneal permeability of drug is evaluated by 
using goat eye cornea. The fresh whole eyeball of goat is 
obtained from local butcher‟s shop and transported in 
laboratory in normal saline solution (4
o
C). Cornea is then 
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carefully excised along with 2-4 mm of surrounding sclera 
tissue and wash with saline solution. Excise cornea is place 
in between donor and receptors compartment of Franz 
diffusion cell in such a way that epithelial surface face the 
donor compartment. Receptor compartment is filled with 
freshly prepared ATF. Whole assembly is placed on 
thermostatically controlled magnetic stirrer, temperature 
(37
o
C ± 0.5
o
C) as well as stirring rate (20 rpm) is 
maintained. 1ml prepared formulation is placed in donor 
compartment. Samples (0.5ml) are withdrawn at 
predetermined time interval of 1hr to 5hr and same volume 
is replaced by ATF. Samples are then diluted upto 10ml and 
analysed on either UV spectrophotometer or HPLC [70, 
71]. 
4.6 Ocular irritation study 
As there is ban on Draize study in many countries 
ocular irritation study of in situ formulation can be 
performed by one of the following method. 
4.7 Histological study  
To evaluate effect of in situ formulation on corneal 
structure and study the irritation potential, corneas are 
removed from the eyes of freshly sacrificed goat and 
incubated at 37
o
C for 5 hrs in formulation. Sodium 
dodecylsulfate (SDS) solution in phosphate buffer saline 
(PBS) 0.1% (w/w) is used as the positive control. After 
incubation, corneas are washed with PBS and immediately 
fixed in formalin (8%, w/w). Tissues are dehydrated in an 
alcohol gradient, placed in melted paraffin and solidified in 
block form. Cross sections are cut, stained with 
haematoxylin and eosin (H&E). Cross sections are observed 
microscopically for any modifications [72]. 
4.8 Hen’s Egg Test-Chorioallantoic Membrane (HET-
CAM) 
HET-CAM test is performed by incubating the 
eggs for 10 days at 37
o
C and relative humidity of about 
70% with automatic turning once per hour. After incubation 
period, a portion of each egg shell is removed and a drop of 
water is placed onto the air sack membrane to avoid 
capillary damage during its removal. The CAM is then 
carefully exposed to 0.1 ml or 0.1 gm of test substances, 
which is washed-off with normal saline solution after 30 
sec of exposure. Simultaneously, CAM is exposed to saline 
solution (negative control) and 1% SDS solution (positive 
control). Each CAM is observed microscopically after 5 
minutes for haemorrhage, lysis and coagualtion. An 
irritation score (IS) is calculated for each CAM by using 
following formula; 
𝐼𝑆 =
 301− 𝐻𝑒𝑚𝑜𝑟𝑟ℎ𝑎𝑔𝑒 
300
× 5 +
(301− 𝐿𝑦𝑠𝑖𝑠)
300
× 7
+
301− 𝐶𝑜𝑎𝑔𝑢𝑙𝑎𝑡𝑖𝑜𝑛
300
× 9 
Irritation score is given according to following 
scheme; 0 = no reaction; 1 = slight reaction; 2 = moderate 
reaction; 3= severe reaction [73, 74].  
4.9 Accelerated stability study 
A stability study for in situ formulation is carried 
out as per ICH guidelines to determine the physical stability 
of the formulation under accelerated storage conditions. 
Formulation is subjected to elevated temperatures and 
humidity conditions of 25±1°C/ 60%RH, 30±1°C/ 65%RH 
and 40 ± 2oC/ 75 ± 5 % RH. Samples are withdrawn at the 
end of 0, 30, 60 and 90 days and then evaluated for active 
drug content [76]. 
 
5. Conclusion 
In situ gelling system is novel and technically 
superior to existing technologies. It solves various problems 
of conventional drug delivery systems including poor 
bioavailability, systemic side effect and poor patient 
adherence to therapy. It can be used for commercial 
manufacturing. In situ drug delivery systems can be 
breakthrough in treatment of number of ocular diseases. 
This new avenue of research would ultimately lead to a 
wide variety of practical therapeutic applications. 
However, these systems have proved their 
effectiveness theoretically and much more efforts yet 
required producing such systems on commercial scale. In 
situ gel system is more idyllic approach for treatment of 
ocular diseases. Several promising in vitro and in vivo 
results have been reported so far with different types of in 
situ gelling systems. In future, more study is required for 
reconnoitring in situ formulation in treatment of various 
ocular chronic diseases. 
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